MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037)

NCT00076869 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Aspergillosis

Interventions

DRUG: MK0991, caspofungin acetate
DRUG: Comparator: amphotericin B
DRUG: Comparator: lipid formulation of amphotericin B and/or azole

Sponsor

Merck Sharp & Dohme LLC